What do systematic reviews say?

Summary of findings table ‐ Adjunctive therapies in addition to land‐based exercise therapy vs placebo adjunctive therapies

• Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee 2022 · Cochrane Headline outcomes only
  no estimate extracted
  20 studies · 1361 participants
  Low

Tramadol vs placebo

• Tramadol for osteoarthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 2550 participants
  Moderate

Tramadol in combination with acetaminophen vs placebo

• Tramadol for osteoarthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 614 participants
  Moderate

Celecoxib vs placebo

• Celecoxib for osteoarthritis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1622 participants
  High

MAOIs vs placebo

The review found no eligible studies for this question.

• Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Paracetamol vs placebo

Paracetamol showed no clear difference in physical function (WOMAC function 0–100) compared with placebo (high certainty).

• Paracetamol versus placebo for knee and hip osteoarthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 2354 participants
  High

Acupuncture vs placebo or sham acupuncture

• Acupuncture for treating fibromyalgia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 56 participants
  Moderate

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

• Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 308 participants
  High

Diacerein vs placebo

• Diacerein for osteoarthritis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1006 participants
  Moderate

Chondroitin with or without glucosamine vs placebo or control

• Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1163 participants
  Moderate

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

Abatacept (2 and 10mg/kg) + DMARDs/biologic probably leads to higher improvement in physical function (HAQ: greater than 0.3 increase… compared with placebo + DMARDs/biologic (moderate certainty).

• Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
  RR 1.62 [1.35, 1.95]
  1 study · 638 participants
  Moderate

Corticosteroids (dexamethasone) vs placebo

Corticosteroids (dexamethasone) may leads to higher number of participants with normal physical joint function ‐ normal… compared with placebo (low certainty).

• Corticosteroids for septic arthritis in children 2018 · Cochrane Headline outcomes only
  RR 1.32 [1.12, 1.57]
  1 study · 100 participants
  Low

Electromagnetic field treatment vs placebo

• Electromagnetic fields for treating osteoarthritis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 197 participants
  Low

Antidepressants vs placebo

Antidepressant showed no clear difference in mean change in physical function from baseline (0–100 WOMAC Total… compared with placebo (high certainty).

• Antidepressants for hip and knee osteoarthritis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 1909 participants
  High

Celecoxib vs placebo

• Celecoxib for rheumatoid arthritis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 706 participants
  Low